DGAP-News: Geratherm Medical AG: Stepping back
DGAP-News: Geratherm Medical AG
/ Key word(s): Personnel
Geratherm Medical AG: Stepping back
21.04.2021 / 12:03
The issuer is solely responsible for the content of this announcement.
Corporate News
Geratal, 21 April 2021
Stepping back
Geratherm Medical AG: Mr. Rudolf Bröcker, Chairman of the Supervisory Board of Geratherm Medical AG, has informed us that he will step back from his position on the Supervisory Board at the end of the Annual General Meeting on June 11, 2021.
Dr. Frank, member of the board of Geratherm Medical AG, has also informed us that he will step back from his position as board member of the company at the end of the general meeting on June 11, 2021. GMF Capital GmbH, which holds more than 25% of the voting rights in the company, proposes the election of Dr. Gert Frank to the Supervisory Board at the Annual General Meeting on June 11, 2021.
Geratherm Medical AG
Investor Relations
Geratherm Medical AG
Fahrenheitstraße 1
99331 Geratal
Phone: +49 (0)36205 98 111
Fax: +49 (0)36205 98-115
E-Mail: [email protected]
Web: www.geratherm.com
Firmensitz: Fahrenheitstraße 1, 99331 Geratal / GERMANY
Vorstand: Dr. Gert Frank (Vorsitzender), Dipl.-Kfm. Christian Frick
Aufsichtsratsvorsitzender: Dipl.-Kfm. Rudolf Bröcker
Registergericht: Amtsgericht Jena HRB 111 272
Short company profil:
Geratherm Medical is an internationally operating medical products enterprise with the business areas Healthcare Diagnostic, Medical Warming Systems, Cardio/Stroke and Respiratory. Our company's roots are in temperature measurement in the medical sphere. In this business area we offer a broad spectrum of products, most of which have unique selling points. We supply our customers/patients with high-quality products ranging from thermometers to complex warming systems for use in the operating theatre and by emergency rescue services and MRI Diagnostic Incubator Systems for premature babies and newborns. In the Cardio business area we concentrate on the development of products for the detection of atrial fibrillation as a measure to prevent strokes. The Respiratory segment develops and markets products for the assessment of pulmonary function. In all mainly business areas, Geratherm has patent-protected basic technologies at its disposal. We regard ourselves as a research-based medical products company with a clear focus on medical diagnostic devices that generate vital data. Geratherm shares have been listed in the Prime Standard segment of the Frankfurt Stock Exchange since the year 2000. Geratherm Medical continues to be represented in the German Entrepreneurial Index and in the German Healthcare Index.
Contact:
Dr. Gert Frank
21.04.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
|
Language: |
English |
Company: |
Geratherm Medical AG |
|
Fahrenheitstraße 1 |
|
99331 Geratal |
|
Germany |
Phone: |
+49 (0)36205 98-0 |
Fax: |
+49 (0)36205 98-1 15 |
E-mail: |
[email protected] |
Internet: |
www.geratherm.com |
ISIN: |
DE0005495626 |
WKN: |
549562 |
Listed: |
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: |
1187189 |
|
End of News |
DGAP News Service |
1187189 21.04.2021
Die wichtigsten Finanzdaten auf einen Blick
|
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
Umsatzerlöse1 |
21,03 |
21,52 |
19,85 |
27,47 |
23,94 |
25,85 |
20,96 |
EBITDA1,2 |
1,77 |
2,80 |
2,35 |
4,35 |
2,31 |
3,55 |
4,27 |
EBITDA-Marge3 |
8,42 |
13,01 |
11,84 |
15,84 |
9,65 |
13,73 |
|
EBIT1,4 |
0,63 |
1,99 |
1,05 |
3,04 |
0,59 |
2,07 |
2,55 |
EBIT-Marge5 |
3,00 |
9,25 |
5,29 |
11,07 |
2,46 |
8,01 |
12,17 |
Jahresüberschuss1 |
0,22 |
0,83 |
0,29 |
1,90 |
0,33 |
1,08 |
1,67 |
Netto-Marge6 |
1,05 |
3,86 |
1,46 |
6,92 |
1,38 |
4,18 |
7,97 |
Cashflow1,7 |
2,47 |
1,35 |
1,54 |
3,92 |
0,92 |
2,79 |
1,47 |
Ergebnis je Aktie8 |
0,14 |
0,23 |
0,11 |
0,41 |
0,02 |
0,19 |
0,21 |
Dividende8 |
0,47 |
0,40 |
0,25 |
0,40 |
0,12 |
0,15 |
0,50 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2023 - Kostenfrei herunterladen.
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: Baker Tilly
|
INVESTOR-INFORMATIONEN |
©boersengefluester.de |
Geratherm Medical |
WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
549562 |
3,320 |
Verkaufen |
17,97 |
KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
15,81 |
27,16 |
0,57 |
16,52 |
KBV |
KCV |
KUV |
EV/EBITDA |
0,82 |
12,21 |
0,86 |
4,09 |
Dividende '22 in € |
Dividende '23 in € |
Div.-Rendite '23 in % |
Hauptversammlung |
0,15 |
0,10 |
3,01 |
16.08.2024 |
Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
- |
15.08.2024 |
- |
20.06.2024 |
Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
-18,77% |
-24,11% |
-38,52% |
-40,71% |
|
|